<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924818</url>
  </required_header>
  <id_info>
    <org_study_id>PO16020*</org_study_id>
    <nct_id>NCT02924818</nct_id>
  </id_info>
  <brief_title>Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases</brief_title>
  <acronym>RINNOPARI</acronym>
  <official_title>Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases: The RINNOPARI Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <brief_summary>
    <textblock>
      Chronic inflammatory pulmonary diseases including chronic obstructive pulmonary disease&#xD;
      (COPD), interstitial lung diseases (ILD), bronchiectasis, and cystic fibrosis (CF) are&#xD;
      characterized by lung inflammation and remodelling. Clinical, functional, microbiological,&#xD;
      biological, pathological and prognosis features are highly variable and heterogeneous. A&#xD;
      precise phenotyping is a key-element to better understanding the pathophysiology of these&#xD;
      chronic inflammatory diseases and to develop innovative treatment strategies.&#xD;
&#xD;
      The objectives of this prospective study is to analyze the clinical, demographic, biological,&#xD;
      morphological, pathological, and microbiological characteristics in a cohort of patients&#xD;
      diagnosed with COPD, ILD, bronchiectasis, and CF. The associations between clinical,&#xD;
      demographic, biological, morphological, pathological, and microbiological features will be&#xD;
      assessed.&#xD;
&#xD;
      The Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases (the&#xD;
      RINNOPARI Project: Recherche et Innovation en Pathologie Respiratoire Inflammatoire) is a&#xD;
      monocentric study conducted at the University Hospital of Reims, France. Adult patients (&gt;18&#xD;
      year-old) followed at the University Hospital of Reims and diagnosed with COPD, ILD,&#xD;
      bronchiectasis, or CF will be considered for inclusion. Patients will sign an informed&#xD;
      consent for inclusion. Exclusion criteria include &quot;subjects protected by the law&quot; as required&#xD;
      by the French authorities. Control patients with no respiratory diseases after clinical and&#xD;
      pulmonary function tests assessment will be also included. The expected number of patients&#xD;
      included is 225 (COPD, n=100; CF, n=25; bronchiectasis, n=25; ILD, n=25; controls, n=50).&#xD;
      Inclusion will be conducted for 36 months from September 2016 (9/30/2016) to September 2019&#xD;
      (9/30/2019).&#xD;
&#xD;
      For all COPD, ILD, bronchiectasis, and CF patients included, data will be registered at&#xD;
      inclusion, and at follow-up visits for 10 years. Patients will be followed-up as usual care&#xD;
      with no specific therapeutic intervention. For control patients, data will be registered at&#xD;
      inclusion with no follow-up.&#xD;
&#xD;
      Data will be registered in a centralized anonymized database. The characteristics of the&#xD;
      patients will be described as mean and standard deviation for quantitative data and as number&#xD;
      and percentages for qualitative data. Comparisons and associations between groups and&#xD;
      variables will be analyzed by Student, Wilcoxon, Chi2, Fischer exact, and Spearman tests as&#xD;
      applicable. A p&lt;0.05 will be considered as significant.&#xD;
&#xD;
      This study should help to better characterize clinical, demographic, biological,&#xD;
      morphological, pathological, and microbiological characteristics and phenotypes in chronic&#xD;
      inflammatory respiratory diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Anticipated">November 2031</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific measurements: cytokines (Th1, Th2, Th17, Tc1, Tc2, Tc17) measurements in blood sample</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific measurements: cytokines (Th1, Th2, Th17, Tc1, Tc2, Tc17) measurements in blood sample</measure>
    <time_frame>up to 10 years</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Chronic Inflammatory Pulmonary Diseases</condition>
  <arm_group>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical assessment</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>questionnaires</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pulmonary function test</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood test</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>microbiology</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>histology</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>imaging</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (&gt;18 year-old) with COPD, CF, bronchiectasis or ILD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 year-old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gaëtan Deslée</last_name>
    <phone>326787611</phone>
    <phone_ext>33</phone_ext>
    <email>gdeslee@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien JOLLY</last_name>
      <phone>326788472</phone>
      <phone_ext>33</phone_ext>
      <email>djolly@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

